Skip to content

Amphastar Pharmaceuticals

US · AMPH #3194 by market cap
28.25 +0.14 +0.50%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 28.16 +0.18%
After-hours 28.26 +0.04%
29.7118.1228.252026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on AMPH?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +20.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 10.0% of float.
  • Analyst tilt is Sell.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A+

The radar needs all six factors. Available grades are shown below.

Valuation A-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 13.0x Better than 66%
Forward P/E 11.1x Better than 73%
Price / Sales 1.7x Better than 63%
P/E vs own 5-yr range 35th pctl Better than 71%
Growth B+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 13.0% Better than 72%
Net income CAGR (3Y) 2.4% Better than 45%
Free cash flow CAGR (3Y) 22.2% Better than 67%
Profitability B+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 49.5% Better than 62%
Operating margin 19.5% Better than 75%
Net margin 13.6% Better than 69%
Return on equity 12.9% Better than 62%
Return on invested capital 7.9% Better than 60%
Momentum A

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 30.8% Better than 98%
6-month return 53.4% Better than 96%
12-month return (ex latest month) -3.3% Better than 30%
Distance below 52-week high 8.9% Better than 86%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.0x Better than 81%
Debt to assets 40.3% Better than 27%
Interest coverage 5.9x Better than 60%
Free cash flow / net income 121.3% Better than 52%
Analyst View N/A

What the Street thinks: share of Buy ratings and upside to the average target.

Not enough data to grade this factor.

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -3.81%
1M +8.91%
3M +30.30%
6M +56.25%
YTD +5.49%
1Y +11.40%
3Y -50.08%
5Y +37.74%

Key statistics

Price & volume

Prev close
28.11
Open
28.14
Day range
27.79 - 28.70
Avg price
28.23
Volume
498.49K
Turnover
14.07M
Amplitude
3.24%
52-week range
16.65 - 31.00

Valuation

P/E
13.92
P/E (TTM)
12.96
P/B
1.48
EPS
2.03
Net profit
86.58M
Net assets
814.57M

Share structure

Market cap
1.20B
Float cap
887.31M
Shares out
42.65M
Float shares
31.41M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 81% of range
16.65 31.00

8.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+1.33M net over the window

Short interest

Shares short
4.26M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Amphastar Pharmaceuticals (AMPH)?

Amphastar Pharmaceuticals last traded at 28.25. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Amphastar Pharmaceuticals's market cap?

About 1.20B.

What is the P/E ratio of Amphastar Pharmaceuticals?

The trailing twelve-month P/E is 12.96, below its own 5-year average of 17.73 — in the middle of its historical range (35.28% percentile). See the Valuation tab for the full history.

Does Amphastar Pharmaceuticals pay a dividend?

Amphastar Pharmaceuticals does not currently pay a regular dividend.

Is Amphastar Pharmaceuticals a buy according to analysts?

The consensus of 2 analysts is a Sell rating, with an average 12-month price target of 23.00, which implies 18.6% downside from the current price. This is not investment advice.

What is Amphastar Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Amphastar Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.

Amphastar Pharmaceuticals discussion 0 comments

Add a comment